Alnylam stock surged 62% due to sales growth and pipeline progress, showing positive outlook.

From Nasdaq.: 2025-03-14 07:40:00

Alnylam Pharmaceuticals (ALNY) is focused on developing RNAi therapeutics in genetic medicines, cardio-metabolic disease, and hepatic infectious disease. ALNY’s stock surged 62% in the past year due to increasing sales of its drugs and pipeline progress. ALNY’s portfolio includes Amvuttra, Givlaari, Oxlumo, and Onpattro, with significant revenue growth.

Amvuttra, ALNY’s lead drug, generated $970.5 million in sales in 2024, up 74% year-over-year. ALNY also markets Givlaari and Oxlumo, with combined sales of $422.9 million in 2024. The company collaborates with Novartis for Leqvio to treat hypercholesterolemia. ALNY’s pipeline includes vutrisiran and cemdisiran, showing promise for expansion.

ALNY’s pipeline includes vutrisiran and cemdisiran, with potential label expansions and new treatment options. ALNY collaborates with Regeneron for mivelsiran in treating Alzheimer’s disease. ALNY is also working with Roche to develop zilebesiran for hypertension, showing promising results in phase II studies. The successful development of these candidates will boost ALNY’s growth.

Alnylam’s stock holds a Zacks Rank 3 (Hold). The company’s collaboration with Roche for zilebesiran in hypertension treatment shows promising results. ALNY’s pipeline includes various candidates in different phases of development, with potential for significant growth. Keep an eye on ALNY for further updates and developments in the healthcare sector.



Read more at Nasdaq.: Alnylam Rallies 62% in a Year: Can the Stock Maintain This Momentum?